BRKR Stock Recent News

Bruker (BRKR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.

While the top- and bottom-line numbers for Bruker (BRKR) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Bruker (BRKR) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.64 per share a year ago.

Evaluate the expected performance of Bruker (BRKR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.

Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.

NanoString announced Wednesday that it will be acquired by Bruker, ending the company's restructuring process that included a Chapter 11 bankruptcy plan.

Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.

Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.